Role of MOG Antibodies in the Differential Diagnosis of Acquired Demyelinating CNS Syndromes in Children

Background: MOG antibodies have been recently reported in recurrent ON, ADEM and AQP4 negative NMO, but less frequently in MS. Objective was to assess the prognostic value of MOG antibodies in the differential diagnosis of first acute inflammatory and demyelinating events alone and in combination with markers (e.g., OCBs, CSF cell count). In this prospective multicenter hospital based study, clinical course, CSF- and MRI studies, outcome, MOG-,AQP4-, and EBV- antibody status of 252 children with a first demyelinating event and a follow up of at least two years were reviewed.